Result of GM and Change of Name to Evocutis plc

RNS Number : 5770Q

Syntopix Group plc

20 October 2011

 



Press Release

20 October 2011

Syntopix Group plc (to be renamed Evocutis plc)

("the Company")

Result of General Meeting and Change of Name to Evocutis plc

On 27 September 2011, Syntopix Group plc (AIM:SYN), the dermatological experts delivering healthcare innovation to the cosmetic, consumer healthcare and pharmaceutical industries, announced a proposed change of name of the Company from Syntopix Group plc to Evocutis plc, conditional upon the passing of a resolution by shareholders at a general meeting of the Company.  

The directors of the Company are pleased to announce that shareholders approved the resolution earlier today.

It is expected that the Company will change its name to Evocutis plc, its AIM symbol to EVO and its website address to www.evocutis.com with effect from 7.00am on Tuesday 25^th  October 2011.

- Ends -

For further information, please contact:

Syntopix Group plc (to be renamed Evocutis plc)
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman
Zeus Capital Ltd
Tom Rowley/Andrew Jones	Tel: [phone]
	www.zeuscapital.co.uk

XCAP Securities Plc
Karen Kelly/John Grant	Tel: [phone]
	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins/Adam Michael/ Jamie Hooper	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

About Evocutis plc

With a rich portfolio of new product opportunities Evocutis offers antimicrobial expertise to the cosmetic, consumer healthcare and pharmaceutical industries.

Additionally, Evocutis is uniquely able to combine research for laboratory testing, advanced skin models and clinical testing to offer a complete service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products that actually work.

Evocutis works with companies at all stages of the product development pipeline offering R&D solutions from ownable technology platforms through to tailored research, and now provides an independent commercial testing facility to the pharmaceutical and healthcare industries. Unique characteristics of its colonised full thickness model of human skin (LabSkin^TM) allow rapid, cost effective screening of, for example, anti-aging, anti-inflammatory and antimicrobial ingredients and products for use on skin.

Evocutis also offers high quality contract research services specialising in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research.

When it comes to topical antimicrobial innovation the Evocutis focus is simple: intelligent and specialised R&D input. 

For further information, please see www.syntopix.com or www.evocutis.com.

 

END

 

 

MSCQBLFLFBFBFBF